Overview

A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E

Status:
COMPLETED
Trial end date:
2025-05-22
Target enrollment:
Participant gender:
Summary
This is a phase 1, prospective, single-center, randomized sequence, open label, 2-way crossover study comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E. It is planned to randomize approximately 16 healthy male and female subjects. All study periods will be completed during a single residency, the overall duration of residency will be 11 days (10 nights).
Phase:
PHASE1
Details
Lead Sponsor:
Baxter Healthcare Corporation
Treatments:
alpha-glycerophosphoric acid